This clinical trial is focused on studying the effects of a treatment for anemia, a condition where the body doesn’t have enough healthy red blood cells to carry adequate oxygen to the tissues. The treatment being tested is an intravenous medication called Ferric Carboxymaltose, which is a form of iron given through a vein. Iron is an essential mineral that helps the body produce red blood cells. The study will also involve the use of mannitol, a type of sugar alcohol used in medical settings, and electrolytes, which are minerals in the body that help balance the amount of water and acidity in the blood.

The purpose of the study is to see if giving 1000 mg of Ferric Carboxymaltose immediately after certain types of surgeries, such as liver or pancreatic surgery, or complex aortic surgery, can improve recovery. These surgeries often involve significant blood loss, which can lead to severe anemia. The study will look at various outcomes, including the number of blood transfusions needed, the severity of anemia after surgery, and changes in quality of life five weeks after surgery. Participants will be randomly assigned to receive either the Ferric Carboxymaltose treatment or a placebo.

The study will follow participants for up to five years to observe the long-term effects of the treatment. Researchers will assess whether the treatment affects recovery, the rate of complications after surgery, and the ability to receive further cancer treatments if needed. They will also monitor for any side effects during the treatment and the follow-up period. The goal is to determine if this iron treatment can help improve outcomes for patients undergoing major surgeries with significant blood loss.